BioNTech, moderna, curevac, covid-19, coronavirus, entstof:
20200320AD
BTM Innovations, publiek-private vennootskap, Apeiron, SRI International, Iktos, antivirale middels, AdaptVac, ExpreS2ion Biotechnologies, pfizer, janssen, sanofi,

In 16 Maart het die Europese Kommissie aangekondig dat hy 80 miljoen euro aangebied het om die Duitse maatskappy CureVac te ondersteun om die werk aan die koronavirus-entstof te versnel. Hierdie inligting verskyn die dag nadat die Duitse regeringsbronne gesê het die Donald Trump-administrasie is op soek na 'n manier om toegang tot hierdie potensiële entstof te kry. Beteken dit dat daar net een maatskappy is wat werk aan 'n oplossing wat so belangrik is vir die mensdom? WIE (Wêreldgesondheidsorganisasie) publiseer data oor 13 sulke ondernemings op sy webwerwe, en die Global Data-databasis dui op 30 instellings wat aan hierdie onderwerp werk. Is daar dalk kanse vir 'n vinnige oplossing vir ons probleme? Die duiwel is altyd in die besonderhede.
Amptelik is daar net een onderneming - American Moderna - wat 'n kliniese proeffase deurgemaak het waar die entstof by mense getoets word. Toetse word in die Verenigde State by die Washington Institute of Health Research in Seattle uitgevoer. So 'n vinnige ontwikkeling van 'n potensiële entstof is ongekend en was moontlik omdat wetenskaplikes die ervaring kon gebruik met koronavirusse wat die SAID- en MERS-epidemies veroorsaak het. Ondanks rekordhoudende werk, selfs al is die entstof veilig en doeltreffend teen die virus, blyk dit nie minstens een jaar beskikbaar te wees nie.
Alle ander spelers wat 'n entstof teen coronavirus wil ontwikkel, is tans op die mees gevorderde prekliniese stadium. Die prekliniese fase is navorsing in laboratoriums en diere wat eers oor ongeveer anderhalf jaar tot inenting kan lei. Dit is moeilik om te sê wie die wedloop vir die entstof wen, maar die grootste kanse is nie nuwe ondernemings nie, maar groot farmaseutiese ondernemings.

Die Duitse maatskappy CureVac werk saam met 'n openbare instelling in Oslo, die sogenaamde Koalisie vir epidemiese paraatheid (CEPI). Hulle werk aan 'n mRNA-gebaseerde entstof. Soos die Amerikaanse reus Moderna mRNA, wil CureVac bewys dat mRNA-entstowwe vinniger sal ontwikkel en vervaardig word as tradisionele entstowwe, en is van voorneme om vroeg in die somer na die kliniese fase I-studies te gaan.
Soos CureVac, die Duitse maatskappy BioNTech, wat mRNA-entstowwe teen kanker en griep ontwikkel, is die onderwerp van 'n potensiële vennootskap met die farmaseutiese reus Pfizer om 'n entstof teen die Covid19-virus te ontwikkel. Sanofi en Janssen werk saam met die American Biomedical Advanced Office for Research and Development (BARDA) en is ook in 'n prekliniese stadium.
Baie kleiner projekte is ook aan die gang. Op Maandag is EUR 7 miljoen se subsidies onder die Horizon2020-program aan die Deense publiek-private konsortium toegewys: biotegnologie-ondernemings ExpreS2ion Biotechnologies en AdaptVac. Die konsortium beoog om binne 12 maande 'n kliniese fase I / IIa-ondersoek vir die entstof te begin.

Alhoewel die vroegste entstowwe in die prekliniese fase tot die somer kan wees, sal regulators waarskynlik een tot twee jaar menslike toetse benodig om te verseker dat die entstof veilig en effektief is. Nadat goedkeuring verkry is, kan ondernemings die entstof op kommersiële skaal begin vervaardig en versprei, wat ook lank duur. Samevattend sien die wêreld die goedgekeurde Covid-19-entstof eers teen middel 2121.
Dit blyk egter dat die entstof nie die enigste verlossing is nie. Baie maatskappye verwag om nuwe antivirale middels te ontwikkel of huidige eksperimentele medisyne aan te pas om die nuwe virus te beveg. Dit is 'n moeilike taak, want in teenstelling met bakterieë, skuil virusse in ons eie selle. Dit beteken dat medisyne wat die virus stop meer gereeld ons selle beïnvloed, wat newe-effekte kan veroorsaak.
Die Paryse maatskappy Iktos wat medisyne vervaardig deur kunsmatige intelligensie het met die Amerikaanse chemiese maatskappy SRI International begin. Die doel van die samewerking is om nuwe antivirale middels vir die behandeling van Covid19 en ander soorte virusse te ontwikkel. Die Oostenrykse biotegnologieonderneming Apeiron het einde Februarie met die kliniese fase II-proeflopie van 'n kandidaatmedikasie teen Covid-19 begin. Die proteïenmedisyne het reeds fase I- en II-studies in die behandeling van akute longbesering voltooi en dit sal na verwagting werk deur die proteïen wat koronavirus bind tydens die inval van die long na te boots. daar is ook baie projekte wat daarop gemik is om die gebruik van goedgekeurde antivirale middels in die behandeling van Covid-19 te verander. Dit het die voordeel dat die veiligheid van die middel reeds bekend is en die mark vinniger kan bereik. Navorsers van Göttingen en Berlyn, Duitsland, ondersoek tans die potensiaal van kamostat mesylaat - 'n middel wat in Japan goedgekeur is vir die behandeling van pankreatitis.

http: //www.e-manus.pl/


BioNTech, moderna, curevac, covid-19, coronavirus, vaccine:
20200320AD
BTM Innovations, public-private partnership, Apeiron, SRI International, Iktos, antiviral drugs, AdaptVac, ExpreS2ion Biotechnologies, pfizer, janssen, sanofi, 

On March 16, the European Commission announced that it offered EUR 80 million in support to the German company CureVac to accelerate work on the coronavirus vaccine. This information appears the day after German government sources said the Donald Trump administration was looking for a way to get access to this potential vaccine. Does this mean that there is only one company that is working on a solution that is so important for humanity? WHO (World Health Organization) publishes data on 13 such companies on its pages, and the Global Data database indicates 30 institutions working on the topic. So are there any chances for a quick remedy for our troubles? The devil is always in the details.
Officially, there is only one company - American Moderna - that has gone to the phase of clinical trials where the vaccine is being tested on humans. Tests are conducted in the United States at the Washington Institute of Health Research in Seattle. Such rapid development of a potential vaccine is unprecedented and was possible because scientists were able to use the experience of related coronaviruses that caused SARS and MERS epidemics. Despite record fast work, even if the vaccine proves safe and effective against the virus, it will not be available for at least a year.
All other players seeking to develop a coronavirus vaccine are currently at most pre-clinical stage. The preclinical stage is research in laboratories and animals that can only lead to vaccines in about a year and a half. It's hard to say who wins the race for the vaccine, but the biggest chances are not start-ups, but big drug companies.

The German company CureVac cooperates with a public institution based in Oslo, the so-called Coalition for Epidemic Preparedness (CEPI). They are working on an mRNA-based vaccine. Like the American giant Moderna mRNA, CureVac wants to prove that mRNA vaccines will be developed and manufactured faster than traditional vaccines and intends to move to Phase I clinical trials early this summer.
Like CureVac - the German company BioNTech, which develops mRNA vaccines for cancer and influenza - is the subject of a potential partnership with the pharmaceutical giant Pfizer to develop a vaccine for the Covid-19 virus. Sanofi and Janssen cooperate with the American Biomedical Advanced Office for Research and Development (BARDA) and are also at a preclinical stage.
Many smaller projects are also underway. On Monday, EUR 2.7 million in subsidies under Horizon 2020 was allocated to the Danish public-private consortium: biotechnology companies ExpreS2ion Biotechnologies and AdaptVac. The consortium intends to launch a phase I / IIa clinical trial for the vaccine within 12 months.

While the earliest vaccines may be in Phase I preclinical studies up to summer, regulatory authorities will probably require one to two years of human testing to ensure that the vaccine is safe and effective. After obtaining approval, companies can start producing and distributing the vaccine on a commercial scale, which also takes a long time. In summary, the world can see the approved Covid-19 vaccine only around mid-2021.
However, it turns out that the vaccine is not the only salvation. Many companies expect to develop new antiviral drugs or adapt current experimental drugs to fight the new virus. This is a difficult task, because unlike bacteria, viruses hide in our own cells. This means that medicines that stop viruses affect our cells more often, which can cause side effects.
The Paris company Iktos, dealing in the creation of drugs using artificial intelligence, has started cooperation with the American chemical company SRI International. The goal of the collaboration is to develop new antiviral drugs for the treatment of Covid-19 and other types of viruses. The Austrian biotechnology company Apeiron began a phase II pilot clinical trial of the candidate drug against Covid-19 at the end of February. The protein drug has already completed Phase I and II studies in the treatment of acute lung injury and is expected to act by mimicking the protein with which coronavirus binds during lung invasion. there are also many projects aimed at changing the use of approved antiviral drugs for the treatment of Covid-19. This has the advantage that the drug's safety is already known and can reach the market faster. Researchers at institutions in Göttingen and Berlin, Germany, are currently investigating the potential of kamostat mesylate - a drug approved in Japan for the treatment of pancreatitis.

http://www.e-manus.pl/